Changing Perspective for Treatment of Chronic Kidney Disease / / Giacomo Garibotto.

Chronic kidney disease (CKD) has become an enormous worldwide health problem, both in developed and less developed countries. The incidence and prevalence of CKD is high, and is associated with increased mortality and morbidity. Of note, CKD is the 12th most common primary cause of death, accounting...

Full description

Saved in:
Bibliographic Details
VerfasserIn:
Place / Publishing House:Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022.
Year of Publication:2022
Language:English
Physical Description:1 online resource (158 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02310nam a2200277 i 4500
001 993562105004498
005 20230219185946.0
006 m o d
007 cr |||||||||||
008 230219s2022 sz o 000 0 eng d
035 |a (CKB)4920000001372690 
035 |a (NjHacI)994920000001372690 
035 |a (EXLCZ)994920000001372690 
040 |a NjHacI  |b eng  |e rda  |c NjHacl 
050 4 |a RC902  |b .G375 2022 
082 0 4 |a 616.61  |2 23 
100 1 |a Garibotto, Giacomo,  |e author. 
245 1 0 |a Changing Perspective for Treatment of Chronic Kidney Disease /  |c Giacomo Garibotto. 
264 1 |a Basel :  |b MDPI - Multidisciplinary Digital Publishing Institute,  |c 2022. 
300 |a 1 online resource (158 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on: online resource; title from PDF information screen (MDPI, viewed February 19, 2023). 
520 |a Chronic kidney disease (CKD) has become an enormous worldwide health problem, both in developed and less developed countries. The incidence and prevalence of CKD is high, and is associated with increased mortality and morbidity. Of note, CKD is the 12th most common primary cause of death, accounting for about 1 million deaths per year worldwide. CKD and end-stage renal disease are characterized by the progressive development of a series of complications, such as anemia, hyperkalemia, hypervolemia, mineral and bone disorders (CKD-MBD), metabolic acidosis, hyperuricemia and wasting; all of these complications have been shown to be associated with adverse outcomes, and can contribute either individually or in association to the cardiovascular morbidity and mortality observed in CKD. While at this time CKD progression is not treated with high efficacy, new biomarkers of kidney fibrosis have become available in recent years and new treatments for kidney fibrosis and cell loss could become soon available. In addition recent progress in our understanding of CKD pathophysiology together with the development of novel therapeutic agents has led to a renewed attention on the treatment of CKD-associated metabolic complications which are now are amenable to therapeutic interventions. All these important issues are addressed in this volume. 
650 0 |a Kidneys  |x Diseases. 
776 |z 3-0365-2795-8 
906 |a BOOK 
ADM |b 2023-03-01 01:57:16 Europe/Vienna  |f system  |c marc21  |a 2022-09-22 08:09:39 Europe/Vienna  |g false 
AVE |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337957780004498&Force_direct=true  |Z 5337957780004498  |8 5337957780004498